HemaSphere (Jun 2022)

P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL.

  • G. Martinelli,
  • A. Santoro,
  • C. Gambacorti-Passerini,
  • S. Vives Polo,
  • S. R. Solomon,
  • S. Mukherjee,
  • E. Lech-Maranda,
  • M. Yair Levy,
  • A. Wierzbowska,
  • M. Calbacho-Robles,
  • G. Marconi,
  • M. Benedetta Giannini,
  • I. Cano,
  • L. Torres Miñana,
  • E. Acuña-Cruz,
  • N. Angelosanto,
  • A. Galleu,
  • S. Baldini,
  • S. Blotta,
  • F. Ravandi,
  • P. Montesinos

DOI
https://doi.org/10.1097/01.HS9.0000844968.45342.3d
Journal volume & issue
Vol. 6
pp. 419 – 420

Abstract

Read online

No abstracts available.